Evidence map›Paper›PMID 38254758›Full record

ArticleCancers2024

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data.

Ibon Gurruchaga Sotés, M Carmen Gómez-Mateo, María Eugenia Ortega Izquierdo, Javier Martínez-Trufero

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ibon Gurruchaga SotésDepartment of Medical Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-2519-8079
M Carmen Gómez-MateoDepartment of Pathology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.ORCID 0000-0002-0990-7480
María Eugenia Ortega IzquierdoInstituto de Investigación Sanitaria de Aragón, 50009 Zaragoza, Spain.
Javier Martínez-TruferoInstituto de Investigación Sanitaria de Aragón, 50009 Zaragoza, Spain.ORCID 0000-0002-0997-2573
Hospital Universitario Miguel Servet · ESInstituto de Investigación Sanitaria Aragón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of gemcitabine and dacarbazine has exhibited efficacy in terms of progression-free survival (PFS) and overall survival (OS) for aSTSs, albeit without robust confirmation from larger clinical trials.

methodsWe conducted a retrospective study in a single institution involving aSTS patients treated with gemcitabine and dacarbazine.

results95 patients were assessed, pointing to a benefit in PFS of 3.5 months and an OS of 14.2 months. Patients with translocated histotypes had better PFS, while those with platelet-lymphocyte ratios (PLRs) surpassing a specific threshold or lower albumin levels had poorer overall survival.

conclusionsThis study validates previous findings from three phase I-II trials, affirming the utility of this treatment approach in routine clinical practice.

Indexed as

advanced soft tissue sarcomabiomarkerdacarbazinegemcitabineprognostic index

Identifiers

PMID38254758
PMCPMC10813902
OpenAlexW4390670315

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.